Company Overview and News

Artis REIT: Better Portfolio Mix, But Is It A Buy?

2018-03-31 seekingalpha
Over the past few years, Artis REIT has reduced its exposure to the real estate market in Alberta.
Upvote Downvote

TheBaron VII: Tough Market Movement Spells Opportunity

2018-03-28 seekingalpha
The overall portfolio had a weak month due mainly to one company's continued share price weakness, with slight moves downwards in most of the portfolio.
Upvote Downvote

Is This REIT's 7.1% Yielding Dividend Worth The Investment?

2018-03-28 seekingalpha
It has an attractive dividend yield of 7.1% and development projects that should improve its net operating income over time.
Upvote Downvote

Should You Buy Allied Properties And Its 3.9%-Yielding Dividend?

2018-03-26 seekingalpha
Allied Properties REIT (OTCPK:APYRF) (TSX:AP.UN) owns a portfolio of high-quality urban office properties in Canada. The REIT has a healthy development pipeline that should significantly expand its portfolio. It also has an excellent track record of dividend growth since its inception. However, its share price is currently trading at a premium. Investors are encouraged to check other REITs before making their investment decision.
Upvote Downvote

Trapeze Asset Management Q4 2017 Commentary - 'It's Never One Thing'

2018-03-06 seekingalpha
Includes detailed analysis of Trapeze Asset Management's positions in ORXGF, ATXMF, EDYYF, MKRYF, ALK, SBBTF, MDT, TJX, TAP, SIEGY, SNY, JNJ, HHC, HUSKF, CCT, RA, MGRUF, TPRFF.
Upvote Downvote

Buying More Morguard: Undervalued On Every Front

2018-02-26 seekingalpha
Morguard trades at 65% of book value that is almost exclusively real estate marked quarterly to fair value.
Upvote Downvote

The Lean, Mean Income Machine: Volume 1

2018-02-01 seekingalpha
We have been writing for Seeking Alpha for since May 2017. During that time we have covered a lot of our existing long positions and gone in detail occasionally on our macro outlook. We have however skipped a few updates on stocks as there was very little additional information to justify a full article. We have also been asked for more details on our portfolio by our followers. To deal with both these, we decided to give a portfolio overview and explain our methodology.
Upvote Downvote

This 6.9% Diversified REIT Is Deeply Undervalued

2018-01-03 seekingalpha
The well covered 6.9% yield, higher insider ownership and possibility of a buyout give us patience to wait.
Upvote Downvote

Cominar REIT: What The Accelerated Disposition Means

2018-01-02 seekingalpha
Cominar REIT (OTCPK:CMLEF) decided it was probably not a great idea for its investors to have a quiet Christmas. On December 18 it announced a radical transaction to sell its properties. Management had previously guided on this quite differently. First the properties were supposed to be sold in multiple tranches. Second, this would begin the middle of 2018. Based on this new information we reanalyzed the REIT's potential cash flow, dividend coverage and forward valuation.
Upvote Downvote

Will This REIT Cut The Dividend Again In 2018?

2017-12-12 seekingalpha
We initially recommended Cominar REIT (OTCPK:CMLEF) in mid-July. We doubled down on Cominar REIT after the dividend was cut and it has paid off nicely with the stock higher than before the cut and up significantly from the panic lows. We now examine whether the dividend is sustainable post the property sales.
Upvote Downvote

Research Reports on Real Estate Stocks Northview Apartment REIT, Temple Hotels, Plaza Retail REIT, and Morguard REIT

2017-11-28 accesswire
LONDON, UK / ACCESSWIRE / November 28, 2017 / Active-Investors' free stock reports for this morning include these Toronto Exchanges' equities from the REITs industry: Northview Apartment REIT (TSX: NVU-UN), Temple Hotels (TSX: TPH), Plaza Retail REIT (TSX: PLZ-UN), and Morguard REIT (TSX: MRT-UN). Access our complimentary up-to-the-minute research reports by becoming an online member now:
Upvote Downvote

Do You Buy This 6%-Yielding High-Quality Retail REIT?

2017-09-30 seekingalpha
In spite of its being one of the worst-performing REITs on the TSX and trading at a cheap valuation, we are not interested in initiating a position.
Upvote Downvote

Morguard REIT Trading At 45% Discount To NAV With 62% Insider Ownership

2017-09-14 seekingalpha
Insiders own over 60% of the firm and are happy to increase positions with little fanfare.
Upvote Downvote

Daily Coverage on Real Estate Stocks, Pure Multi Family REIT, Morguard REIT, Automotive Properties REIT, and Partners REIT

2017-09-13 accesswire
LONDON, UK / ACCESSWIRE / September 13, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select stocks with the REITs industry and that trades on the Toronto Exchanges. This Morning, our team has regrouped these stocks for study: Pure Multi-Family REIT, Morguard REIT, Automotive Properties REIT, and Partners REIT.
Upvote Downvote

Read Your REIT Balance Sheets: The Case Of Morguard North American

2017-08-03 seekingalpha
Very few people actively enjoy reading balance sheets and financial statements. I don't, but it's a necessary evil. Relying on numbers coming out of stock screeners is often misleading. To illustrate, let's examine the history of Morguard North American Residential REIT (OTC:MNARF), which just released Q2 earnings this morning and is trading up slightly on the news.
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...